Market open
Nektar Therapeutics/$NKTR
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Nektar Therapeutics
Nektar Therapeutics is a pharmaceutical company focused on the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. The company is focused on discovering and developing medicines in the field of immunotherapy. Its clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases (e.g. rezpegaldesleukin and NKTR-0165, respectively) and cancer (e.g. NKTR-255).
Ticker
$NKTR
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
137
Website
NKTR Metrics
BasicAdvanced
$188M
Market cap
-
P/E ratio
-$0.84
EPS
0.61
Beta
-
Dividend rate
Price and volume
Market cap
$188M
Beta
0.61
52-week high
$1.93
52-week low
$0.46
Average daily volume
2.2M
Financial strength
Current ratio
4.239
Quick ratio
3.649
Long term debt to equity
377.602
Total debt to equity
421.592
Interest coverage (TTM)
-5.47%
Management effectiveness
Return on assets (TTM)
-22.64%
Return on equity (TTM)
-161.63%
Valuation
Price to revenue (TTM)
2.201
Price to book
4.37
Price to tangible book (TTM)
4.37
Price to free cash flow (TTM)
-1.153
Growth
Revenue change (TTM)
5.53%
Earnings per share change (TTM)
-46.11%
3-year revenue growth (CAGR)
-2.46%
3-year earnings per share growth (CAGR)
-32.50%
What the Analysts think about NKTR
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Nektar Therapeutics stock.
NKTR Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
NKTR Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
NKTR News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Nektar Therapeutics stock?
Nektar Therapeutics (NKTR) has a market cap of $188M as of December 12, 2024.
What is the P/E ratio for Nektar Therapeutics stock?
The price to earnings (P/E) ratio for Nektar Therapeutics (NKTR) stock is 0 as of December 12, 2024.
Does Nektar Therapeutics stock pay dividends?
No, Nektar Therapeutics (NKTR) stock does not pay dividends to its shareholders as of December 12, 2024.
When is the next Nektar Therapeutics dividend payment date?
Nektar Therapeutics (NKTR) stock does not pay dividends to its shareholders.
What is the beta indicator for Nektar Therapeutics?
Nektar Therapeutics (NKTR) has a beta rating of 0.61. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.